Sherman Matthew L 4
4 · Deciphera Pharmaceuticals, Inc. · Filed Feb 17, 2023
Insider Transaction Report
Form 4
Sherman Matthew L
EVP & Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-02-15+65,900→ 65,900 totalExercise: $15.48Exp: 2033-02-14→ Common Stock (65,900 underlying) - Award
Common Stock
2023-02-15+16,488→ 89,116 total - Sale
Common Stock
2023-02-16$15.10/sh−971$14,661→ 88,145 total
Footnotes (3)
- [F1]The reporting person was awarded 16,488 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026.
- [F2]This sale was to cover tax liabilities in the vesting of restricted stock.
- [F3]This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023.